4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

8-K/A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

D - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

NT 10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

DEFR14A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

Licensed technology positions Company at forefront of new quantum-class computing paradigm Q/C Technologies, Inc. (NASDAQ:QCLS), formerly TNF Pharmaceuticals, Inc. (NASDAQ: TNFA), ("Q/C" or "the Company"), today announced that its common stock will begin trading under the new ticker symbol "QCLS" beginning today at the market open. The Company's new name Q/C Technologies represents its recent strategic pivot into quantum-class computing with exclusive global rights to LightSolver's light-speed laser processing unit (LPU), the world's first light and laser-based computing system, for application in quantum class cryptocurrency verticals. "The official transition to Q/C Technologies and

New trading symbol QCLS effective Thursday, September 25, 2025 Licensed technology positions Company at forefront of new quantum-class computing paradigm TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("Q/C" or the "Company") today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol "QCLS" on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company's common stock will continue to trade under its current ticker symbol "TNFA." The new name Q/C Technologies represents the Company's recent strategic pivot into quantum-class computing with exclusive global rights to

TNF Pharmaceuticals Inc. (NASDAQ:TNFA), ("TNF" or the "Company") today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days. "We are pleased to have regained compliance with Nasdaq's listing standards. This milestone comes as we work to build a strong strategic platform for growth and shareholder value. We will be updating shareholders on our progress in the weeks ahead,"

Management to present on Wednesday, September 10, 2025, at 8:00 a.m. ET TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company") today announced its participation in the H.C. Wainwright & Co. 27th Annual Global Investment Conference taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. TNF's presentation is scheduled for Wednesday, September 10, 2025, at 8:00 a.m. ET. Presentation Details: Date and time: September 10, 2025, at 8:00 a.m. ET1 Location: Lotte New York Palace Hotel, New York City, Rutherford Room, 4th Floor Conference registration: hcwevents.com/annualconference In addition to th

Financing priced at a 44% premium to market Led by a top strategic investor with significant participation from existing stockholders TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company") today announced the closing of a $7.0 million private placement financing of convertible preferred stock with the Company's largest strategic stockholder and other existing stockholders. The private placement involved the sale of 7,000 shares of preferred stock, with a stated value of $1,000 per share, convertible into 1,400,000 million shares of the Company's common stock at an initial conversion price of $5.00, and accompanying warrants to purchase up to 1,400,000 shares of the Company's

TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced that it has increased its stake in TNF Pharmaceuticals (NASDAQ:TNFA, "TNF")) by an additional $3 million. The Company does so to help support TNF's recent acquisition of a license with LightSolver, Ltd. ("LightSolver"), a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing accelerator designed to expedite compute-sensitive computations by

First light- and laser-based computing system designed to outperform quantum and supercomputing and solve complex problems unfeasible for GPUs Strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies Supported by strategic investment from TNF's largest stockholder; TNF to pursue name change reflecting new direction TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company") today announced that it has entered into a licensing agreement for an innovative processing accelerator designed to expedite compute-intensive computations In partnership with LightSolver Ltd. ("Li

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that its board of directors has authorized a reverse stock split of the Company's common stock at a ratio of 1 post-split share for every 100 pre-split shares. The Company's common stock will begin trading on a split-adjusted basis upon market open on Tuesday, September 2, 2025. The Company expects to provide operational business updates coinciding with the completion of the reverse stock split. The new CUSIP number for the Company's common stock following the reverse stock split i

Transforms present balance sheet with significant reduction in liabilities Largest shareholder is long-term strategic investor TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. "The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value

Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a nonprofit organization seeking innovative ways to accelerate research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). Together, the parties are expected to initiate a Compassionate Use (Expanded Access) study evaluating TNF's lead candidate isomyosamine as a potential trea

Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the event TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company's lead candidate isomyosamine, a novel oral TNF

SC 13G/A - TNF Pharmaceuticals, Inc. (0001321834) (Subject)